Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Summary
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced the first closing of an investment round raising $46.5 million. Existing investors also participated in this financing, including Flerie Invest AB, Oriella Limited (CBG, chaired by Vincent Tchenguiz), Pavilion Capital, Hadasit Bio Holdings Ltd (HBL) and Mirae Asset. “The successful financing round of this respected syndicate of investors is a testament to our breakthrough technology platforms and promising next-generation multifunctional, immunotherapeutic pipeline,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. DSP107 is currently being tested in a Phase 1/2 multicenter, open-label, dose-escalation and expansion study assessing the safety, pharmacokinetics and pharmacodynamics of DSP107 as a monotherapy and in combination with Roche’s PD-L1-blocking checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors. KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor.